TY - JOUR
T1 - Cytokine induced 3-D organotypic psoriasis skin model demonstrates distinct roles for NF-κB and JAK pathways in disease pathophysiology
AU - Todorović, Viktor
AU - McDonald, Heath A.
AU - Hoover, Paul
AU - Wetter, Joseph B.
AU - Marinopoulos, Anastasia E.
AU - Woody, Clarissa L.
AU - Miller, Loan
AU - Finkielsztein, Ariel
AU - Dunstan, Robert W.
AU - Paller, Amy S.
AU - Honore, Prisca
AU - Getsios, Spiro
AU - Scott, Victoria E.
N1 - Funding Information:
Work was performed with the support of the Northwestern University Skin Disease Research Centerfunded by NIH grant AR057216 and Northwestern University Skin Biology & Diseases Resource‐Based Center funded by NIH grant AR075049. The design, study conduct and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review and approval of the publication. No honoraria or payments were made for authorship.
Funding Information:
Spiro Getsios from Northwestern University has served as consultant and has received research funding from AbbVie. Amy S. Paller from Northwestern University has been a consultant with honorarium, an investigator (funding to institution) and on a data safety monitoring committee for AbbVie. Ariel Finkielsztein and Paul Hoover from Northwestern University have no funding to disclose. Heath M. McDonald, Joseph B. Wetter, Anastasia E. Marinopoulos, Clarissa L. Woody, Loan Miller, Robert W. Dunstan, Prisca Honore, Victoria E. Scott and Viktor Todorović are employees of AbbVie.
Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2022/7
Y1 - 2022/7
N2 - Psoriasis vulgaris is an inflammatory skin disease that affects 2%–3% of the population worldwide. One of the major challenges in discovering novel therapies is the poor translatability of animal models to human disease. Therefore, it is imperative to develop human preclinical models of psoriasis that are amenable to pharmacological intervention. Here, we report a 3-D reconstituted human epidermis (RHE) culture system treated with cytokines commonly associated with psoriasis (TNFα, IL-17A and IL-22) that reproduced some key features of the human disease. The effects on epidermal morphology, gene transcription and cytokine production, which are dysregulated in psoriasis were assessed. Certain morphological features of psoriatic epidermis were evident in cytokine-stimulated RHEs, including hypogranulosis and parakeratosis. In addition, RHEs responded to a cytokine mix in a dose-dependent manner by expressing genes and proteins associated with impaired keratinocyte differentiation (keratin 10/K10, loricrin), innate immune responses (S100A7, DEFB4, elafin) and inflammation (IL-1α, IL-6, IL-8, IL-10, IL-12/23p40, IL-36γ, GM-CSF and IFNγ) typical of psoriasis. These disease-relevant changes in morphology, gene transcription and cytokine production were robustly attenuated by pharmacologically blocking TNFα/IL-17A-induced NF-κB activation with IKK-2 inhibitor IV. Conversely, inhibition of IL-22-induced JAK1 signalling with ABT-317 strongly attenuated morphological features of the disease but had no effect on NFκB-dependent cytokine production, suggesting distinct mechanisms of action by the cytokines driving psoriasis. These data support the use of cytokine-induced RHE models for identifying and targeting keratinocyte signalling pathways important for disease progression and may provide translational insights into novel keratinocyte mechanisms for novel psoriasis therapies.
AB - Psoriasis vulgaris is an inflammatory skin disease that affects 2%–3% of the population worldwide. One of the major challenges in discovering novel therapies is the poor translatability of animal models to human disease. Therefore, it is imperative to develop human preclinical models of psoriasis that are amenable to pharmacological intervention. Here, we report a 3-D reconstituted human epidermis (RHE) culture system treated with cytokines commonly associated with psoriasis (TNFα, IL-17A and IL-22) that reproduced some key features of the human disease. The effects on epidermal morphology, gene transcription and cytokine production, which are dysregulated in psoriasis were assessed. Certain morphological features of psoriatic epidermis were evident in cytokine-stimulated RHEs, including hypogranulosis and parakeratosis. In addition, RHEs responded to a cytokine mix in a dose-dependent manner by expressing genes and proteins associated with impaired keratinocyte differentiation (keratin 10/K10, loricrin), innate immune responses (S100A7, DEFB4, elafin) and inflammation (IL-1α, IL-6, IL-8, IL-10, IL-12/23p40, IL-36γ, GM-CSF and IFNγ) typical of psoriasis. These disease-relevant changes in morphology, gene transcription and cytokine production were robustly attenuated by pharmacologically blocking TNFα/IL-17A-induced NF-κB activation with IKK-2 inhibitor IV. Conversely, inhibition of IL-22-induced JAK1 signalling with ABT-317 strongly attenuated morphological features of the disease but had no effect on NFκB-dependent cytokine production, suggesting distinct mechanisms of action by the cytokines driving psoriasis. These data support the use of cytokine-induced RHE models for identifying and targeting keratinocyte signalling pathways important for disease progression and may provide translational insights into novel keratinocyte mechanisms for novel psoriasis therapies.
KW - ABT-317
KW - IKK-2 inhibitor IV
KW - IL-17A
KW - IL-22
KW - TNFα
UR - http://www.scopus.com/inward/record.url?scp=85125625656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125625656&partnerID=8YFLogxK
U2 - 10.1111/exd.14551
DO - 10.1111/exd.14551
M3 - Article
C2 - 35213752
AN - SCOPUS:85125625656
VL - 31
SP - 1036
EP - 1047
JO - Experimental Dermatology
JF - Experimental Dermatology
SN - 0906-6705
IS - 7
ER -